Hence, NEPC is clinically suspected when a prostate cancer is seen with absent or a low/moderate rise in PSA, presents at advanced stage, or has a predominance of visceral and/or bone metastatic disease (Figure 2). The gene discussed is KLK3; the disease is prostate carcinoma.